{"product_id":"biolegend-115534","title":"Biolegend, 115534, PerCP\/Cyanine5.5 anti-mouse CD19 Antibody, 100μg","description":"\u003cp\u003eCD19 is a 95 kD glycoprotein also known as B4. It is a member of the Ig superfamily, expressed on all pro-B to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: Mouse CD19-expressing K562 human erythroleukemia cells\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with PerCP\/Cyanine5.5 under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.* PerCP\/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)Green Laser (532 nm)\/Yellow-Green Laser (561 nm)\u003cbr\u003e\nApplication Notes: Additional reported applications (for the relevant formats) include: immunofluorescence7.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Shoham T, et al. 2003. J. Immunol. 171:4062. (FC) Goodyear CS, et al. 2004. J. Immunol. 172:2870. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. (FC) Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (FC) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Phan TG, et al. 2007. Nat. Immunol. 8:992. (FC) Hayashida K, et al. 2008. J. Biol. Chem. 283:19895. (IF) PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Stadnisky MD, et al. 2011. Blood. 117:5133. (FC) PubMed Perlot T, et al. 2012. J. Immunol. 188:1201. (FC) PubMed Olive V, et al. 2013. Elife. 2:822. PubMed Miyai T, et al. 2014. PNAS. 111:11780. PubMed\u003cbr\u003e\nProduct Citations: Bradley CP et al. 2017. Cell host \u0026amp; microbe. 22(5):697-704 . PubMed Lang J, et al. 2020. Nat Commun. 11:1338. PubMed Deng G, et al. 2023. Cancers (Basel). 15:. PubMed Fan L, et al. 2020. J Immunol Res. 2020:3032425. PubMed Mills EL, et al. 2022. Cell Metab. 34:140. PubMed Laffleur B, et al. 2022. Sci Immunol. 7:eabn2738. PubMed Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed Potempa M, et al. 2022. J Immunol. 208:1742. PubMed Miller CM, et al. 2020. J Virol. 94:00:00. PubMed Zhou J, et al. 2019. Immunity. 50:403. PubMed Frisbee AL, et al. 2019. Nat Commun. 10:2712. PubMed Webb LMC, et al. 2021. Aging Cell. 20:e13295. PubMed Lancaster JN, et al. 2019. Nat Commun. 10:2220. PubMed Kobayashi T, et al. 2019. Cell. 176:982. PubMed Smith D, et al. 2011. PLoS One. 7:e1002284. PubMed Wei H, et al. 2021. Malar J. 20:89. PubMed Guzmán M, et al. 2021. Mucosal Immunol. 14:1347. PubMed Yousif AS, et al. 2020. Immunity. 54(2):235-246.e5. PubMed Zhu X, et al. 2017. Arch Oral Biol. 10.1016\/j.archoralbio.2017.03.010. PubMed Eastman A, et al. 2016. J Immunol . 194: 5999-6010. PubMed Wang X, et al. 2016. PLoS Pathog. 12: 1005367. PubMed Woodruff MC et al. 2018. Cell reports. 25(2):321-327 . PubMed Bratti M, et al. 2022. Front Immunol. 13:1029759. PubMed Gopinathan G, et al. 2022. Mol Cancer Ther. 21:1030. PubMed Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed Santiago M, et al. 2010. J Immunol. 185:1114. PubMed Yoshihara E, et al. 2020. Nature. 606:586. PubMed Fachi JL, et al. 2020. J Exp Med. 217:00:00. PubMed Sochalska M, et al. 2016. Oncogene. 10.1038\/onc.2016.362. PubMed Cuff AO, et al. 2020. Frontiers in Immunology. 1.930555556. PubMed Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed Krementsov DN, et al. 2018. Front Immunol. 9:1622. PubMed Palathingal Bava E, et al. 2022. JCI Insight. 7:. PubMed Wagage S, et al. 2014. J Immunol. 192:1661. PubMed Daniel CJ, et al. 2022. Mol Cancer Res. 20:1151. PubMed McFarland AP, et al. 2021. Immunity. 54(6):1320-1337.e4. PubMed Sangesland M, et al. 2020. Cell Reports. 32(8):108065. PubMed Uddin MJ, et al. 2022. Mucosal Immunol. 15:165. PubMed White C, et al. 2015. J Immunol. 194:697. PubMed Ariyoshi Y, et al. 2016. Gene Ther. 10.1038\/gt.2016.7. PubMed Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed Zhu H, et al. 2019. Nat Commun. 10:1084. PubMed LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed Ding P, et al. 2022. Bone Res. 10:42. PubMed Hajas A, et al. 2013. Hum Immunol. 19:93. PubMed DiToro D, et al. 2020. Immunity. 650:52. PubMed Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed Holzki J, et al. 2015. J Virol. 89: 9886 - 9895. PubMed Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed Maniati E, et al. 2020. Cell Rep. 30:525. PubMed Glasenapp A, et al. 2021. Circ Res. 129:369. PubMed Ghezraoui H, et al. 2018. Nature. 560:122. PubMed Li S, et al. 2013. Virology. 443:143. PubMed Velazquez VM, et al. 2017. Mol Ther Methods Clin Dev. 0.277083333. PubMed Royzman D, et al. 2019. Front Immunol. 10:633. PubMed Heil J, et al. 2021. Nat Commun. 12:6963. PubMed Fedele C, et al. 2021. J Exp Med. 218: . PubMed Li S, et al. 2014. J Immunol. 193:306. PubMed Peng V, et al. 2022. Nat Immunol. 23:619. PubMed Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed Ioanna E Galani et al. 2017. Immunity. 46(5):875-890 . PubMed Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed\u003cbr\u003e\nRRID: AB_2259869 (BioLegend Cat. No. 115533) AB_2072925 (BioLegend Cat. No. 115534)\u003cbr\u003e\nStructure: Ig superfamily, associates with CD21 and CD81, 95 kD\u003cbr\u003e\nDistribution: Pro-B cells to mature B cells (during development), follicular dendritic cells\u003cbr\u003e\nFunction: Modulates B cell activation and differentiation\u003cbr\u003e\nLigand\/Receptor: CD21, CD81, Leu-13\u003cbr\u003e\nCell Type: B cells, Dendritic cells\u003cbr\u003e\nBiology Area: Costimulatory Molecules, Immunology\u003cbr\u003e\nMolecular Family: CD Molecules\u003cbr\u003e\nAntigen References: 1. Fearon DT. 1993. Curr. Opin. Immunol. 5:341. 2. Krop I, et al. 1996. Eur. J. Immunol. 26:238. 3. Krop I, et al. 1996. J. Immunol. 157:48. 4. Tedder TF, et al. 1994. Immunol. Today 15:437.\u003cbr\u003e\nGene ID: 12478\u003cbr\u003e\nUniProt: View information about CD19 on UniProt.org\u003cbr\u003e\nClone: 6D5\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: B4\u003cbr\u003e\nIsotype: Rat IgG2a, κ\u003cbr\u003e\nQ: How stable is PerCP\/Cyanine5.5 tandem as compared to PerCP alone?\u003cbr\u003e\nA: PerCP\/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46862477066409,"sku":"115534","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/biolegend-115534","provider":"Iright","version":"1.0","type":"link"}